Under construction – not a live service
Sign in

2026-525700-10-00RecruitingPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers

Source: EU CTIS (euclinicaltrials.eu) · Last updated 8 Jun 2026

Next steps

Status (registry)
Recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
280 (estimated)
First submitted
6 Mar 2026
Start date
8 Jun 2026
Lead sponsor
Syremis Therapeutics Ltd.
EU CT number
2026-525700-10-00

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 280
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adult volunteers to test the safety and effects of ST‑905‑AG1.

Age
18 Years to 64 Years
Sex
All sexes can join.

This trial only enrols healthy participants. The registry sentence this rests on: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
BiotrialRennesFranceRecruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.